

PAREXEL International  
Imaging Investigator Site Operations Manual



**INVESTIGATOR SITE  
OPERATIONS MANUAL  
NOVARTIS - CAIN457K2340 (SURPASS)**

Project:	Novartis – CAIN457K2340 (SURPASS)
Document File Name:	236483 Investigator Site Operations Manual
Document Revision:	4.0
Version Date:	26 Nov 2018
Author's Name	Omkar Kayal

*Proprietary Statement: This operations manual is a proprietary document provided by PAREXEL Informatics in support of the **Novartis Protocol CAIN457K2340 (SURPASS)**. All material contained herein is confidential and proprietary to PAREXEL Informatics. Do not distribute or duplicate.*

PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

## Copyright Page

Copyright© 2018 PAREXEL International Corporation. All rights reserved.

The material presented in this document and contained herein is proprietary and confidential to PAREXEL International and its subsidiaries and is intended for PAREXEL employees and its clients use only. The material is to be used for the purpose for which it was delivered or made available to you subject to the terms and conditions (if any) of applicable licenses. Each User shall maintain the confidentiality of the material and shall not disclose, distribute, reproduce, or otherwise disseminate, in whole or part, any part of this document or the information contained herein to any third party, without the prior written permission of PAREXEL International. Any unauthorized use or disclosure of this document or the information contained herein, including any resale, reproduction, or any attempt to do so, is strictly prohibited.

Information in this document is subject to change without notice and supersedes all earlier versions for this product.

Perceptive MyTrials, LIQUENT, ClinPhone, DataLabs and IMPACT are trademarks or registered trademarks of PAREXEL International Corporation or its subsidiaries. All other trademarks are property of their respective owners and hereby acknowledged.

PAREXEL International  
Imaging Investigator Site Operations Manual

**Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0**

---

**REVISION HISTORY**

<b>Date</b>	<b>Author</b>	<b>Version</b>	<b>Description of Revision</b>
26 Oct 2017	Omkar Kayal	1.0	Initial Release of Document
14 Mar 2018	Omkar Kayal	2.0	Added Section 2.2 Re-screening Subjects Updated section 2.6 PAREXEL Contact Information Updated section 3.2 Site Survey Completion Updated section 3.3 Test Transfer Acquisition Updated section 4.3 Image Data Transfer via Perceptive eTransfer (Preferred)
25 Jul 2018	Omkar Kayal	3.0	Updated 2.1 Study Background – Imaging Schedule table Updated section 4.3 Image Data Transfer via Perceptive eTransfer (Preferred)
26 Nov 2018	Omkar Kayal	4.0	Updated section 2 Study Background – Imaging Schedule table

PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

**Table of Contents**

<b>1</b>	<b>Abbreviations and Acronyms .....</b>	<b>5</b>
<b>2</b>	<b>Introduction .....</b>	<b>6</b>
2.1	<i>Study Background .....</i>	6
2.2	<i>Re-screening Subjects.....</i>	7
2.3	<i>Purpose of this Manual.....</i>	8
2.4	<i>Start Up Package Components.....</i>	8
2.5	<i>Responsibilities.....</i>	9
2.6	<i>PAREXEL Contact Information.....</i>	9
2.7	<i>Study Flowchart .....</i>	10
<b>3</b>	<b>Site Standardization Procedures .....</b>	<b>11</b>
3.1	<i>Roles and Responsibilities .....</i>	11
3.2	<i>Site Survey Completion.....</i>	12
3.3	<i>Test Transfer Acquisition.....</i>	12
3.4	<i>Test Transfer Preparation, Tracking and Transfer Please refer to sections 4.2 - 4.7.....</i>	13
3.5	<i>Site Standardization Completion.....</i>	13
<b>4</b>	<b>Image Processing Procedures.....</b>	<b>14</b>
4.1	<i>Image Acquisition.....</i>	14
4.2	<i>Preparation and Tracking of Images.....</i>	15
4.3	<i>Image Data Transfer via Perceptive eTransfer (Preferred).....</i>	15
4.4	<i>Image Transfer via Courier.....</i>	18
4.5	<i>Case Acceptance .....</i>	19
4.6	<i>Query Process.....</i>	19
4.7	<i>MyQueries Portal .....</i>	20
4.8	<i>Requesting Support.....</i>	22
<b>5</b>	<b>Confirmation of Imaging Specific inclusion/exclusion criteria: .....</b>	<b>23</b>
<b>6</b>	<b>Sample Forms .....</b>	<b>26</b>
6.1	<i>Case Acceptance Notification.....</i>	26
6.2	<i>Case Query Notification .....</i>	27
6.3	<i>Request Support Form.....</i>	28
6.4	<i>Imaging Study Tracking Log.....</i>	29
6.5	<i>Media Labels.....</i>	29

PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

**1 Abbreviations and Acronyms**

<b>CAN</b>	Case Acceptance Notification
<b>CD</b>	Compact Disc
<b>CIL</b>	Core Imaging Laboratory
<b>CQN</b>	Case Query Notification
<b>DICOM</b>	Digital Imaging and Communications in Medicine
<b>eTransfer</b>	electronic Transfer
<b>IAG</b>	Image Acquisition Guidelines
<b>IRA</b>	Imaging Research Associate
<b>IT</b>	Information Technology
<b>QC</b>	Quality Control
<b>SOM</b>	Site Operations Manual

# PAREXEL International

## Imaging Investigator Site Operations Manual

**Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0**

### 2 Introduction

#### 2.1 Study Background

A phase IIIb, randomized, partially-blinded, active-controlled, multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability, and efficacy up to 2 years in patients with active ankylosing spondylitis, please reference the Study Protocol.

This Investigator Site Operations Manual provides instructions for the imaging component of the NOVARTIS CAIN457K2340 (SURPASS) study. This document is specifically related to the management of imaging data acquisition, including shipment, tracking, and quality control.

All imaging scans will be acquired in a standardized manner, following pre-established Image Acquisition Guidelines (IAG) developed by PAREXEL Informatics and approved by NOVARTIS. Images will be submitted to PAREXEL for processing and independent analysis. Imaging data for all subjects will be acquired according to the imaging schedule outlined in the protocol, as well as listed in the table below:

CAIN457K2340 Imaging Schedule					
Imaging Data	Screening Period	Treatment Period			
	Screening Visit 1 (Week -10 to -4)	Baseline (Day 1)	Week 16	Week 52	Week 104 <sup>6</sup>
X-Ray cervical and thoraco-lumbar spine <sup>2</sup>	X <sup>1,3</sup>	X <sup>1,3</sup>		X	X
X-Ray sacroiliac joints (AP view) <sup>2</sup>	X <sup>3,4</sup>				X
MRI <sup>5</sup> Spine and SI joints		X	X	X	X

<sup>1</sup>Spinal x-rays (cervical and thoraco-lumbar) to be collected during the screening period to confirm eligibility for subjects with CRP < 5 mg/L. If additional lateral thoracic spine x-ray is available, it may also be submitted for syndesmophyte eligibility review. Subjects with CRP ≥ 5mg/L and confirmed study eligibility should obtain the spinal x-rays at baseline.

<sup>2</sup>SIJ and spinal x-ray image acquisition must follow the vendor's Image Acquisition Guidelines. The SIJ x-ray will be centrally read for eligibility

<sup>3</sup>Re-screening subjects may utilize previous x-rays if taken within the past 3 months according to the imaging criteria

<sup>4</sup>Subjects may utilize previous obtained SIJ x-rays if taken within the past 3 months according to the imaging criteria

<sup>5</sup>MRI only performed in a sub-population of subjects at selected sites. All subjects at the selected MRI site should be considered for the MRI assessment

<sup>6</sup>For all subjects who discontinue from the study, the investigator should ensure that the subject completes the end of treatment visit (Week 104 assessments) 4 weeks after last study treatment of secukinumab or 2 weeks after last study treatment of GP2017. Every attempt should be made to obtain the scheduled x-ray and MRI images at the final visit, unless the last x-ray and/or MRI were taken within 12 weeks before discontinuation.

*Note – All X-Ray Images obtained at Screening will be the Baseline Images for the Efficacy Reads*

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

It is REQUIRED that your X-Ray & MRI facility be qualified by PAREXEL. All Imaging (Including the Screening image) must be performed per Image Acquisition Guidelines. Re-scan will be required in the event the Image Acquisition Guidelines are not followed.

### **Please Notify PAREXEL Immediately of any Equipment Changes/Upgrades**

All X-Ray Screening images are required to be submitted to PAREXEL within 24 hours (1 business day) of acquisition

The X-Ray and MRI Baseline and Post-Baseline images should be submitted within 48 hours (2 Business days) of acquisition

Images received at PAREXEL **MUST NOT CONTAIN** any markings, assessments, or confidential subject information.

You must remove from the images the names of the subject and any other information that can be used to identify the subject and only study specific subject number must be used

Cases will be prepared for independent review for eligibility, interim analyses, database lock(s), or study completion.

PAREXEL is responsible to perform the independent confirmation of Imaging Specific inclusion/exclusion criteria as per protocol for the Screening X-RAY. However the Independent Reviewer findings done during the efficacy reviews are independent assessments and will not be communicated to the sites until final Clinical Study Report. All decisions related to subject care are made at the site by the Primary Investigator(s) including whether the subject should continue on the study. Independent Reviewer(s) will remain blinded to the other assessments made at the investigator sites.

### **2.2 Re-screening Subjects**

Site can utilize previous X-Rays if taken within the past 3 month's according to the imaging criteria. Sites have to notify PAREXEL about the re-screening subject number and its original subject number via email or during eTransfer upload when resubmitting the same scan under re-screening subject number.

If notified via email about re-screening subject details, PAREXEL can use the same X-ray images that were submitted earlier for original subject and can generate the eligibility read results for re-screening subject based on original subject results and share with sites. No additional screening visit submission required in this case.

If submitting same set of images over eTransfer portal, sites have to specify the original subject number when re-screening subject scans are being uploaded for PAREXEL to generate the eligibility read results for re-screening subject based on original subject results and share with sites.

PAREXEL will not perform additional eligibility reads for re-screening subjects if the original subject reads were already completed for the eligibility portion of the study and sites are using same X-ray images for re-screening subject.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

### 2.3 Purpose of this Manual

The purpose of this manual is to provide:

- Contact information for additional assistance
- Description of operating procedures for investigator sites
- Sample forms and Image Tracking Log templates

### 2.4 Start Up Package Components

PAREXEL Informatics will provide the investigator site with the necessary materials listed below to perform the functions associated with this Investigator Site Operations Manual.

- The **Image Acquisition Guidelines (IAG)** is generated by PAREXEL in an effort to standardize all imaging associated with the clinical trial across multiple investigator sites, subjects, and timepoints. The standardized guidelines are distributed to each investigator site participating in this study. Please note that in the IAG, there are separate procedures for acquiring each involved region and varying scanner types across X-RAY & MRI modality. Please also ensure that you keep the IAGs in the study binder.
- The **Imaging Study Tracking Log** is used by the investigator site to document only the courier shipment status of all images related to the clinical trial. The log is updated with information regarding image acquisition, shipment dates, and corresponding shipment tracking numbers. PAREXEL will send a copy of this log in the eSite to sites that are using courier submission.
- The **Media Labels** are completed with subject/visit information and placed on each individual film or media (CD, DVD), making sure not to obscure anatomy, being sent to PAREXEL. Please place the label on the actual media and not the media case.
- The **Case Acceptance Notification (CAN)** is sent from PAREXEL to the investigator site when acceptable imaging data is received. Please see a sample of this form in section 6.1 of this manual.
- The **Case Query Notification (CQN)** is sent from PAREXEL to the investigator site upon receipt of unacceptable imaging data or if any additional clarification will be needed for the respective images. The form will describe the query and indicate the action(s) required to be taken towards submission of acceptable imaging data. Please see a sample of this form in section 6.2 of this manual.
- The **Site Acceptance Form** is sent from PAREXEL to the investigator site when all qualification requirements have been met. This notification informs the site that they have been approved for the imaging portion of the study. The form may also contain recommendations and/or feedback regarding future transfer data.
- The **Request Support Form** is sent from the investigator site to PAREXEL for the purpose of requesting supplies and for asking questions related to technical or operational aspects of the imaging portion of the clinical trial (Direct e-mail or telephone contact may be used as an alternative). Please see a sample of this form in section 6.3 of this manual.

**The preferred option of image submission to PAREXEL is eTransfer. Courier will only be accepted in exceptional cases. If your site is using courier, PAREXEL will deliver a hard copy site kit including shipping materials (see section 3.5 for more information). It will also contain:**

- The **Archive Media Labels** which will need to be completed with the subject and visit information and placed on each individual film or archive media (e.g., CD), making sure not to obscure anatomy. Please place the label on the actual media and not the media case.
- **Additional Site Supplies:** Digital media (e.g. CD), bubble mailers, masking pencils, media labels, and airway bills.

# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

#### 2.5 Responsibilities

The **Core Imaging Laboratory (CIL)** is the centralized facility at PAREXEL Informatics for all processes associated with image data collection and review by Independent Reviewers. PAREXEL is responsible for the receipt, tracking, processing, Quality Control (QC), and archiving of the image data. Data generated by the reviewer(s) are maintained at the CIL and will be transferred to NOVARTIS (or designee) at a specified time.

The **investigator sites** are responsible for enrolling subjects and obtaining imaging per the Image Acquisition Guidelines and study protocol. The investigator site is also responsible for managing image scheduling and for preparing and forwarding image data to the CIL within 24 hours of acquisition for screening and 48 hours for the follow-up visits. Any changes in staff must be communicated to PAREXEL in a timely manner so that access to applicable applications/ portals (e.g., eTransfer portal) is appropriately updated.


#### 2.6 PAREXEL Contact Information

<p><b>Project Team 236483</b> PAREXEL Informatics 2<sup>nd</sup> Federal Street Billerica, MA 01821 USA <a href="mailto:236483-Imaging@PAREXEL.com">236483-Imaging@PAREXEL.com</a> Phone : +1 833-543-1079 PAREXEL will try to respond back to you within 24 hours or sooner.</p>
<p><b>Perceptive eTransfer – Technical Support</b> +1 (888) 315-0790 toll free or +1(321)309-2710 (Global Toll Free Number) <a href="mailto:Support@dicomgrid.com">Support@dicomgrid.com</a> (Available 24/7)</p>
<p><b>Omkar Kayal</b> Project Manager Phone :- +91-40-4437-9835 <a href="mailto:Omkar.Kayal@PAREXEL.com">Omkar.Kayal@PAREXEL.com</a></p>

**Note:** Please use the project specific email address: [236483-Imaging@PAREXEL.com](mailto:236483-Imaging@PAREXEL.com) .

Contacts will change during the study. PAREXEL will send along updated spreadsheets periodically to keep sites informed of new contact information. Please place these updates in the study binder to keep current with communication needs

2.7 Study Flowchart



# PAREXEL International

## Imaging Investigator Site Operations Manual

**Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0**

---

### 3 Site Standardization Procedures

This section details the site standardization procedures for the investigator sites participating in this clinical trial. Please notify the radiology staff in advance of a site initiation process and ensure that the Site Survey and the Image Acquisition Guidelines are reviewed prior to acquiring the test transfer scan or subject imaging. Please note that the test transfer must be submitted and approved by PAREXEL before the site's Site initiation visit (SIV).

Novartis and PAREXEL have agreed that the Test Transfer submission step prior to Imaging Qualification is **Not required if your site is already working with PAREXEL on similar indication with similar imaging requirement**. However In order to ensure that the Image quality requirements are met, we want sites to acquire the images for the first subject only, at the first attempt, and send this to PAREXEL for Quality Check. Please don't scan other subjects until you receive the approval/acceptance notification from PAREXEL for the first subject. Once first subject images are approved, the site can resume enrolling/scanning the other subjects as normal.

This step is very important and must be followed once you start acquiring the First subject Images

#### 3.1 Roles and Responsibilities

R = Responsible for doing the task/document/deliverable  
 A = Accountable for the task/document/deliverable being completed  
 C = Consulted for input and/or in performing/completing the task/document/deliverable  
 I = Informed that the task/document/deliverable has been completed

Task/Document/Deliverable	Principal Investigator*	Study Coordinator	Radiologist/ radiology technician	CRA	PAREXEL
Site Survey completion	C	R	R	A	C
IAG Review	C	R	R	A	C
Site Operational Review	C	R	R	A	C
Study Supply Ordering	I	R	R	C	I
Study Supply Distribution	I	I	I	I	R
Direct Contact from/with sites	I	R	R	A	R
Issue Escalation	R	-	-	R	R

**\*Per GCP, the Principal Investigator is ultimately responsible for all site activities and tasks.**

# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

#### 3.2 Site Survey Completion

---

<b>Performed by:</b>	Study Coordinator or Designee, Radiology Technician, CRA
<b>References:</b>	Site Survey, Image Acquisition Guidelines (IAG)
<b>Scope:</b>	This procedure describes the steps necessary to identify the site contact details as well as the hardware and software used. Please refer to the Site Survey for the specific information needed.

Prior to the start of the site qualification process, Novartis will provide PAREXEL with an investigator site list which will include all necessary site contact information. The CRA will partner with the site and PAREXEL to ensure that the correct communication channels are established.

**Note:** The primary contact of the site for PAREXEL should be either the Study Coordinator or the Radiology Technician.

1. PAREXEL will contact the investigator site providing instructions for completion of the required steps for standardization of image acquisition. PAREXEL will provide the Site Survey for completion and the IAG for reference.
2. The primary site contact or CRA will send the completed Site Survey to PAREXEL.
3. PAREXEL will review the Site Survey and check for completeness. Query or Acceptance feedback will be provided to the site by PAREXEL.

**Note:** A Case Query Notification requires further action from the site; query responses should be provided to the PAREXEL study team within 5 business days or sooner when required.

4. Once the Site Survey has been accepted, and the site is considered trained as site has reviewed the Image Acquisition Guidelines and Site Operations Manual, PAREXEL will request that a test transfer be completed as described in Section 3.3.

#### 3.3 Test Transfer Acquisition

---

<b>Performed by:</b>	Study Coordinator, Radiology Technician
<b>References:</b>	Image Acquisition Guidelines (IAG)
<b>Scope:</b>	This procedure describes the steps necessary to acquire test transfer images and to provide PAREXEL with the necessary scan information. Please refer to the IAG for the specific parameters to be used for image acquisition.

1. Upon completion and submission of the site survey and site is considered trained as site has reviewed the Image Acquisition Guidelines and Site Operations Manual, PAREXEL will request a test transfer from the investigator site. If the test transfer is to be submitted to PAREXEL via courier, then supplies may be requested by the site. Upon site's or CRA request, PAREXEL will provide a prepaid airway bill, shipping supplies, and the necessary media for the imaging submission to be completed and sent to PAREXEL.
2. The radiologist or respective technician will acquire the test transfer images according to the IAG, unless the site is working with PAREXEL on similar indication with similar imaging requirement. The Radiology Technician will save the images to the site preferred media (CD, film, DVD) and maintain a copy of the exam at the facility. A test transfer image should be performed using a phantom. (Phantom is any dense object that is scanned to evaluate the performance of a scanner avoiding potential risk to a living subject. Phantom for test scanning will not be provided by PAREXEL.) If eTransfer is not being used, the technician must de-identify (blind) any information that can be used to identify the subject details contained in the DICOM Header.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

**Note:** If you need to de-identify electronic data and your IT department is unable to help, you may wish to consider whether DicomEditor is appropriate. For more information about this free software, please visit: <http://mirwiki.rsna.org/index.php?title=DicomEditor>. DicomEditor is not a PAREXEL product. We do not endorse it, do not make any representations about its performance, and do not supply any training or support for the software. Please ensure you test DicomEditor prior to using it for study images so that you are sure there are no issues with it.

3. The study coordinator must verify that any information which can be used to identify the subject has been completely masked.
4. If the images are being saved to hardcopy films (Not applicable for MRI), please print two original copies, one will remain at the site and the other is sent to PAREXEL.

### 3.4 Test Transfer Preparation, Tracking and Transfer

*Please refer to sections [4.2 - 4.7](#)*

### 3.5 Site Standardization Completion

---

Once the Site Survey and the Test Transfer have been accepted, PAREXEL will send an eStart-up Kit to the site in 1 business day. PAREXEL will inform the site of the completion of the site standardization process in a Site Acceptance Notification via email.

The kit, which contains all study related documents, will be sent via email to all sites who will be submitting the images electronically to PAREXEL. For those sites that will be using courier as the primary method to submit images, the kit will be sent via a courier and will include the shipping materials.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

### 4 Image Processing Procedures

This section details the image acquisition, collection, and data transfer procedures for the investigator sites participating in this clinical trial. Please notify the radiology staff in advance of a study subject's visit and include the Image Acquisition Guidelines with the image requisition.

#### 4.1 Image Acquisition

---

**Performed by:** Study Coordinator, Radiology Technician  
**Scope:** This procedure describes the steps necessary to acquire study images and to provide PAREXEL with the necessary subject and visit information. Please refer to the Image Acquisition Guidelines for the specific parameters to be used for image acquisition.

1. The radiology or respective technician will acquire the images according to the IAG. The radiology technician will save uncompressed, DICOM format images to the site preferred media (CD, film, DVD) and maintain a copy of the exam at the facility. If eTransfer is not being used, the technician must de-identify (blind) the subject name and any other information that can be used to identify the subject contained in the DICOM Header.

**Note:** If you need to de-identify electronic data and your IT department is unable to help, you may wish to consider whether DicomEditor is appropriate. For more information about this free software, please visit: <http://mirwiki.rsna.org/index.php?title=DicomEditor>. DicomEditor is not a PAREXEL product. We do not endorse it, do not make any representations about its performance, and do not supply any training or support for the software. If you haven't done so already, we suggest you try DicomEditor prior to using it for study images so that you are sure there are no issues with it.

2. The study coordinator must verify that the name of the subject and any other information that can be used to identify the subject have been completely masked and only study specific subject number is used
3. Confidential subject information is defined as individually identifiable information including but not limited to:
  - name (full name or first name and last initial or first initial and last name)
  - social security number
  - home address
  - phone number
  - medical record number
4. If the images are being saved to hard copy films (Not Applicable for MRI), please always print two original copies, one remains at the site and the other is sent to PAREXEL.

# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

#### 4.2 Preparation and Tracking of Images

---

**Performed by:** Study Coordinator or Designee

**Scope:** This procedure describes the methods used to prepare and track images for transfer from the investigator site to PAREXEL. All Screening images are required to be submitted to PAREXEL within 24 hours of acquisition (1 business day). The follow-up images should be submitted within 48 hours of acquisition (2 Business days).

The study coordinator receives the imaging data from the Radiology Department and verifies:

- Images stored on digital media are in **uncompressed DICOM format**
  - No lesion markers or measurements are present
  - Confidential subject information is de-identified.
1. The Study Coordinator will contact the site's Radiology Department if any problems are noted.
  2. The Study Coordinator will complete and affix media labels directly onto the media, CD / DVD.
  3. If hard copy films are to be sent, each film must have a media label attached in a manner that does not obstruct anatomy.
  4. Submitting imaging data containing confidential subject information is not permitted.
  5. The Study Coordinator is responsible for maintaining subject confidentiality by ensuring the imaging technicians de-identify confidential subject information on all exams being submitted on digital media.
  6. Hardcopy films may be masked using the specialized masking pencils. Please contact PAREXEL to request masking pencils if needed.

#### 4.3 Image Data Transfer via Perceptive eTransfer (*Preferred*)

---

**Performed by:** Study Coordinator or designee

**Scope:** This procedure describes the steps used to send images from the investigator site to PAREXEL via eTransfer.

This web-based electronic transfer solution allows investigator sites to transfer de-identified study images to PAREXEL Informatics through an internet browser. The eTransfer website is HIPAA and 21CFR Part 11 compliant.

There are only two requirements to use eTransfer:

1. A computer with internet access
2. JAVA plug-in (already installed on most computers)

Recommended internet browser: Google Chrome (no JAVA plug-in required).

Other compatible internet browsers: Internet Explorer (7, 8, 9 or 10), Safari, or Firefox (all require JAVA for upload).

If JAVA is not installed, the Perceptive eTransfer system will guide the user through the java installation process. If installing the Java plug-in is blocked, the user will contact the Information Technology Administrator at the site.

#### **User Access**

1. The PAREXEL study team will create an account using the email address provided by the Novartis or site as the user login ID. The site user will then receive an email notification containing the account credentials and login instructions.
2. Additional user accounts can be requested by emailing the PAREXEL team at [236483-Imaging@PAREXEL.com](mailto:236483-Imaging@PAREXEL.com)
3. Navigate to the system login page and select the training link to view a 10 minute training clip.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

4. Log into the system and the home page appears:

<https://Perceptive.dicomgrid.com/>



### Sign In

Login

Password

[Forgot your password?](#)

#### Training Video (English)

1. English - Introduction to Perceptive eTransfer
2. Spanish (Spain) - Introduccion a la transferencia electronica de Perceptive
3. French - Presentation du systeme Perceptive eTransfer
4. German - Einfuhrung in Perceptive eTransfer
5. Italian - Introduzione al sistema Perceptive eTransfer
6. Korean - Introduction to Perceptive eTransfer
7. Czech - Uvod do systemu eTransferu spolecnosti Perceptive
8. Portuguese (Brazil) - Introducao ao eTransfer da Perceptive
9. Simplified Chinese - Introduction to Perceptive eTransfer
10. Spanish (Argentina) - Introduccion a la transferencia electronica de Perceptive

5. If login is not successful, please check the credentials again and/or contact the PAREXEL team.

### User Settings

1. The user's name appears in the top right menu of the homepage. Select this to edit:
  - First and/or last name
  - Reset the password
  - Set email notifications

Settings **Defaults** Notifications Request access to an organization

2. To edit notification preferences, the user will select the "Notifications" tab. To receive email notifications, select "On Upload".

### Uploading Images

1. Select the trial/site from the dropdown list. Returning users will see the list of all previously transmitted images for the trial at the site.
2. To upload images, the user will select the trial, then the site from the "Studies" dropdown list, and finally select "Upload Studies".

## Upload Studies

### Choose files to be scanned and verified

Select files for DICOM wrapping (Ctrl+click to select multiple)

No file chosen

**NOTE: If uploading a non-DICOM file (i.e. JPEG, AVI, DXA/IQC files), the user must check the "Select files for DICOM wrapping."**

3. Select "Choose File" and a browsing window will appear. The user will select the folder where the study images are stored and select "Open".


# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

- The “Scanning” symbol will appear when a folder has been selected.



Scanning may take up to a few minutes to complete. Your screen may appear to be frozen. Please be patient.

- The user will complete the trial/subject required information.

### Upload Studies to Novartis - CAIN457K2340 - Site 0000

Choose studies to upload

1.2.392.2000...anon.101369

	Description	Images	Patient Name	DOB	Modality	Study Date
<input checked="" type="checkbox"/>		1			CR	08-24-2011

Site Number

Subject Number

Subject number must be 7 digits, concatenation of a valid 4 digit site number and 3digit subject sequence numberPlease enter 3 digits here.

Visit Name

Screening Date

Is this a re-screen subject?

If Yes, Please enter the original subject number

Modality

Comments

Please enter any deviations here.

- You must provide “Screening Date “only during screening image submission and “Re-Screening Subject” number is optional.
- The user will select “Upload Selected Studies”. As the images upload, a status bar will appear. Do not navigate away from the webpage while the upload is in progress. Open another eTransfer webpage to upload another scan concurrently. Upon successful upload, the following message will be displayed:

Congratulations, your image files were uploaded

	Description	Images	Patient Name	Modality	Study Date
<input checked="" type="checkbox"/>	ANONYMIZED <span style="background-color: green; color: white; padding: 2px;">Uploaded</span>	26	ANON1633	CT	05-29-2012

- If the image upload notification feature is on, the user will receive an email within minutes of a successful upload from Perceptive eTransfer.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

### Viewing Images in the Image Viewer

---

1. Once uploaded, images can be viewed through the browser using the “View study in viewer” button:



NOTE: the viewer is only available if using Google Chrome or Mozilla Firefox.

2. The user can use the scroll to the bottom of the viewer to go through all images.

For technical support, contact the DicomGrid support team by phone at 1-888-315-0790 (available 24/7) or by email at [support@dicomgrid.com](mailto:support@dicomgrid.com) and specific Protocol Number [CAIN457K2340 or PAREXEL Project Number [236483)].

### 4.4 Image Transfer via Courier

---

**Performed by:** Study Coordinator or Designee  
**References:** Imaging Study Tracking Log, Airbill  
**Scope:** This procedure describes the steps used to send images from the investigator site to PAREXEL.

1. The Study Coordinator will use the pre-printed airbills that are provided by PAREXEL for this study.  
**Note:** Additional airbills must be requested directly from PAREXEL
2. Complete the pre-printed airbills that are provided by PAREXEL for this study. Please request new labels from PAREXEL when required using the Request Support Form.

**Sites outside of U.S. will need to complete a commercial invoice.**

Note: Pre-printed stickers do not require any further completion and non-preprinted airbills will not be accepted by the courier. If you are in need of UPS airbills, e-mail PAREXEL at [236483-Imaging@PAREXEL.com](mailto:236483-Imaging@PAREXEL.com) to obtain an electronic airbill to ship images and request additional pre-printed labels.

3. The Study Coordinator will place the hard copy films or digital media in the package for shipment.
4. If hardcopy films are being sent, these will be placed in the padded envelopes that can be provided by PAREXEL. Taping around the edges of the envelope will help to secure the images. Shipping boxes can also be obtained free of charge from the appropriate courier.
5. The date of shipment and airbill tracking number will be recorded on the Imaging Study Tracking Log.  
**Note:** Please ship imaging data to PAREXEL within 24 hours for Screening and 48 hours of acquisition for follow-up visits (do not wait for a subject to be randomized or wait to collect images for multiple timepoints).

The sites will be required to complete **Imaging Study Tracking Log** to document only the courier shipment status of all images related to the clinical trial. The log is updated with information regarding image acquisition, shipment dates, and corresponding shipment tracking numbers and stored locally and is not required to be sent back to PAREXEL.

# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

#### 4.5 Case Acceptance

---

**Performed by:** Study Coordinator or Designee  
**References:** Case Acceptance Notification  
**Scope:** This procedure outlines the actions required by the Study Coordinator upon receipt of a Case Acceptance Notification (CAN). The form will be sent from PAREXEL in a timely manner upon receipt of acceptable image data.

1. PAREXEL will perform a quality assurance check on the imaging data received.
2. A CAN is sent from PAREXEL to the investigator site upon receipt of image data informing the site that the imaging for the timepoint is complete and of acceptable quality.
3. This form may also contain feedback or recommendations for subsequent visits.
4. The CAN also serves as documented resolution to a Query.
5. File the CAN in the study's binder. No further action is required.

#### 4.6 Query Process

---

**Performed by:** Study Coordinator or Designee  
**Scope:** This procedure outlines the actions required by the Study Coordinator upon receipt of a Case Query Notification (CQN) from PAREXEL. A CQN will be sent from PAREXEL in a timely manner. The study coordinator may complete and return the CQN via fax or email or may choose to respond via phone or login to the MyQueries portal to resolve the query.

1. A CQN is sent from PAREXEL to the investigator site upon receipt of unacceptable image data. The query text will describe the issue and indicate the action(s) required to resolve the issue(s).
2. The study coordinator is required to respond within 5 business days of CQN receipt or sooner if required.  
**Note: For the Screening Visit Related Queries must be responded within 1 (One) business day.**
3. If a written response on the CQN is being sent to PAREXEL, the study coordinator is required to maintain a copy of the query response in the study's binder.
4. Do not include any confidential subject information in the CQN response. Only the subject number should be used to identify a subject.
5. The study coordinator or Designee may respond to the query by simply replying to the email, responding to the query form, or updating the response on MyQueries portal. If the site opts to use the query form, it should be printed out, the response should be written on the form, and the form should be scanned and emailed ([236483-Imaging@PAREXEL.com](mailto:236483-Imaging@PAREXEL.com)) back to PAREXEL.
6. If resolution of the query cannot be completed, the site is required to notify PAREXEL. This notification must include a definitive date for when the response to the query will be provided.  
**Note:** Increased frequency when approaching study milestones as requested by Novartis.
7. If the site is unable to successfully resolve the query, PAREXEL may request the assistance of the monitor and notify Novartis of the issue.
8. PAREXEL GQT (Global Query Team) also may reach-out to the study Coordinators/Monitors via phone and address the open queries.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

### **Potential issues include:**

•**ISSUE: Unacceptable image quality**

*Action: Provide better quality images or document no other images are available in the comments field of the Query Form.*

•**ISSUE: Image Acquisition Guidelines were not followed**

*Action: Provide additional images if available or document no other images are available in the comments field of the Query Form.*

•**ISSUE: Missing anatomy**

*Action: Provide additional images or document no other images are available in the comments field of the Query Form.*

### 4.7 MyQueries Portal

**Performed by:** Study Coordinator or Designee  
**Scope:** This procedure describes the process for responding to queries sent from PAREXEL via MyQueries

MyQueries is a web-based service for investigator sites to receive, view, track, and respond to queries from any computer with web access.

1. Study Coordinators will be granted access to MyTrials by default. Please contact the PAREXEL team and request an account for MyTrials if additional users will need access.
2. An email will be sent from Perceptive Customer Care with the following email address: [do-not-reply@perceptive.com](mailto:do-not-reply@perceptive.com) with an activation code.
3. Login to MyTrials @ [WWW.MYTRIALS.COM](http://WWW.MYTRIALS.COM).
  - If you already have an account, log on with your User Name and Password.
  - If you are using MyTrials for the first time, select “register new account” in the “Join MyTrials” box.



The internet browser you are using is not fully supported by all the MyTrials applications. [Find out more information about currently supported browsers by application.](#)

Perceptive MyTrials™ is our single sign on environment that gives you access to all information, data and technologies required to conduct your Perceptive clinical trials and programs.

Whether you are a user at an investigational site, bio/pharmaceutical company or CRO, Perceptive MyTrials aims to simplify how you use eClinical technologies. Our solutions, platform and infrastructure gives you a more seamless user experience.

#### Who is Perceptive Informatics?

Perceptive Informatics is a leading eClinical solutions provider and subsidiary of PAREXEL, focused on helping our users to work efficiently and accelerate the drug development process through our innovative clinical trial solutions. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services.

Learn more about [Perceptive Informatics](#).



#### Perceptive MyTrials Product Suite

The Perceptive MyTrials Product Suite delivers a comprehensive set of integrated clinical technologies that support the clinical trial process. To learn more about the individual technologies please select the area of interest below.

- [DataLabs EDC](#)
- [IMPACT CTMS](#)
- [Perceptive Medical Imaging](#)
- [ClinPhone RTSM](#)
- [ePRO](#)
- [Metrics and Collaboration Tools](#)


For help using our technology solutions, please visit our [Customer Care](#) site.

# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

- After logging into the system or creating a new account, enter the activation key(s) that you have received via email. **\*\*Please note you may receive more than one key\*\***




**Access Request**

To gain access to a new trial or application, or modify existing access rights, enter the key you received via email below, and click the Register button.

Key Activation :

[Register](#) [Clear](#) [Help ?](#)

- All trials that you have access to will appear upon login. Select the desired project.



**MY TRIALS**

Select one or 'All Sponsors' from the list provided:

Filter By:  Search for a Trial: [?]  [Reset](#)

Sponsor	Program	Trial	Alias	Description
Ajax Pharmaceuticals	Program A	<a href="#">Trial A</a>	Trial A	208923-Trial A

1 items in 1 page(s)

[Help ?](#)

- Listed under the MyQueries tab are the new and outstanding queries for the project.




**MYQUERIES**

You have **4** new queries.

You have **12** outstanding queries.

[Search](#) [View closed queries](#)

- Click the links to view the queries.



**MYQUERIES**

Query List

Query Summary

Filter By:  [Search](#) [Clear](#)

Query ID	Site ID	Subject ID	Visit ID	Last Sent Date	Closed Date	Age	Status
7985	0008			27-May-2014	N/A	72 days	Outstanding
7988	0008			27-May-2014	N/A	72 days	Outstanding
7991	0008			27-May-2014	N/A	72 days	Outstanding

# PAREXEL International

## Imaging Investigator Site Operations Manual

### Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

#### Query List (Queries can be filtered by any column header)

- **Subject ID** - If the query is regarding a site issue, this field may be blank.
- **Query ID** - A query with a number after the query ID (e.g., 1234-3) represents the number of times the query was resent.
- **Site ID** - If the query is regarding a site issue, the subject field may be blank.
- **Visit ID** - The visit description. If a query is not associated to a visit, this field may be blank.
- **Last Sent Date** - The date the query was sent or resent from the PAREXEL. The Last Sent Date is updated with every response from the team but may not be the latest date in the query history.
- **Age** - The number of days since the query was created.

#### Status

- **New** - Queries that have not been opened/viewed by the site user. Queries can be new to one user and outstanding to another.
- **Outstanding** - Queries that have not been closed by PAREXEL (only PAREXEL can change the status to 'closed'). Outstanding queries may be filtered by "overdue" and "responded".
  - **Overdue** – A query that has not been responded to within 10 business days. The status remains "outstanding" and will be displayed in red text.
  - **Responded** – A query that a site responded to (the status remains "outstanding").
- **Closed** - Queries that have been closed by the PAREXEL team.

#### Search for Queries

- A user can search for queries, including specific text from the query comments section.
- All fields in the query record are included in the search. The search text must be in English.

#### View Query Details

Select a query from the Query List to view details or to respond. The following information is displayed:

- **Query Comments** - The most recent communication is displayed in this section.
- **Query History** - Click "Show" to see the query history. All communications between PAREXEL and site / monitor users are included.
- **Query Response** - If the selected query is outstanding and the user has the appropriate permissions, the user will be able to send a query response to PAREXEL. The response must be in English. Enter the response into the query response field and select "send".
- To navigate between queries in the list, click Next or Previous at the bottom of the Query Detail Page.

#### 4.8 Requesting Support

---

<b>Performed by:</b>	Study Coordinator or Designee
<b>References:</b>	PAREXEL Informatics Contact Information, Request Support Form
<b>Scope:</b>	This procedure describes the steps taken to request support from PAREXEL for the imaging portion of the CAIN457K2340 clinical trial.

1. For all inquiries and other requests regarding the imaging portion of the clinical study, please contact PAREXEL. Refer to the Contact list (Section 2.6).
2. Upon completion/resolution of the request, PAREXEL will communicate a response via phone or email.  
**Note:** Please use the Request Support Form template when making requests.

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

### 5 Confirmation of Imaging Specific inclusion/exclusion criteria:

PAREXEL is responsible to perform the independent confirmation of inclusion/exclusion criteria as per protocol. Novartis acknowledges that the Central read confirmation is based only on the image data made available to PAREXEL, does not constitute medical advice, and may not be used for patient care. All responsibility for patient care and the final decision whether a patient should be enrolled in the study rests with the principal investigator and not with PAREXEL or its independent readers.

**In the case a patient is screened for enrollment in the study, all images have to be sent to PAREXEL within 24 hours of acquisition. All queries issued by PAREXEL related to a patient in screening need to be answered by the site within 24 hours.** Once all associated queries are closed, PAREXEL will independently assess the screening exams within 5 business days.

Upon completion of the Central read, PAREXEL will send results directly to the sites and related distribution list. Eligibility results will be sent via email with central read result (pdf) attachment.

Study contacts with the following roles will receive the Central read results from PAREXEL:

- Principal Investigator
- Study Coordinator
- Site Monitor
- Clinical Study Manager (If Applicable)
- Novartis Study Leads

In case the site investigator desires clarification regarding the basis of the central read confirmation, the investigator will initiate the contact through Study Monitor.

Note: If the Screening X-RAY SIJ exam has been assessed as Positive the Screening X-Ray SPINE exams will not be presented for the independent review assessment at PAREXEL and no results will be shared for such subjects.

PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

Central Read Results – X-Ray – SIJ

**PAREXEL**  
YOUR JOURNEY. OUR MISSION.™

Novartis CAIN457K2340  
Central mNY Read Results

PAREXEL has completed the expedited central read that was requested for your Novartis CAIN457K2340 subject. Please find the results below and file with the subject's source documents. Please do not hesitate to contact your study monitor with any questions or concerns.

Site ID	<Site ID>
Subject ID	<Subject number from Tracking>
Timepoint Read	Screening
Earliest Scan Date	DD/MMM/YYYY
Unilateral sacroiliitis grade 3-4 on x-ray	Yes (Positive) or No (Negative) or NA (Unable to Evaluate)
Bilateral sacroiliitis grade 2-4 on x-ray	Yes (Positive) or No (Negative) or NA (Unable to Evaluate)
<b>SIJ mNY Radiograph Eligibility Result</b>	Yes (Positive) or No (Negative) or NA (Unable to Evaluate)
Date of Report Generation	DD/MMM/YYYY

PAREXEL is responsible to perform the independent confirmation of Imaging Specific inclusion/exclusion criteria as per protocol. Novartis acknowledges that this assessment is based only on the image data made available to PAREXEL, does not constitute medical advice, and may not be used for patient care. All responsibility for patient care and the final decision whether a patient should be enrolled in the study rests with the principal investigator and not with PAREXEL or its independent readers. Novartis shall ensure that any site receiving information about inclusion/exclusion criteria confirmation has agreed to an acknowledgement that is substantially similar to the acknowledgement in the preceding sentences.

Page 1 of 1

PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

Central Read Results – X-Ray SPINE

**PAREXEL**  
YOUR JOURNEY. OUR MISSION.™

Novartis CAIN457K2340  
Central Read Results

PAREXEL has completed the expedited central read that was requested for your Novartis CAIN457K2340 subject. Please find the results below and file with the subject's source documents. Please do not hesitate to contact your study monitor with any questions or concerns.

Site ID	<Site ID>
Subject ID	<Subject number from Tracking>
Timepoint Read	Screening
Earliest Scan Date	DD/MMM/YYYY
Presence of at least one syndesmophyte	Yes or No or N/A (Unable to Evaluate)
Total Spinal Ankylosis	Yes or No or N/A (Unable to Evaluate)
Date of Report Generation	DD/MMM/YYYY

PAREXEL is responsible to perform the independent confirmation of Imaging Specific inclusion/exclusion criteria as per protocol. Novartis acknowledges that this assessment is based only on the image data made available to PAREXEL, does not constitute medical advice, and may not be used for patient care. All responsibility for patient care and the final decision whether a patient should be enrolled in the study rests with the principal investigator and not with PAREXEL or its independent readers. Novartis shall ensure that any site receiving information about inclusion/exclusion criteria confirmation has agreed to an acknowledgement that is substantially similar to the acknowledgement in the preceding sentences.

Page 1 of 1

# PAREXEL International

## Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

### 6 Sample Forms

#### 6.1 Case Acceptance Notification

This form is sent from PAREXEL to the investigator site upon receipt of acceptable imaging data at PAREXEL.

**PAREXEL** 2 Federal Street  
Billerica, MA 01821, USA  
[236483-imaging@PAREXEL.com](mailto:236483-imaging@PAREXEL.com)

---

Acceptance Communication – CAIN457K2340

---

To:	"To" Contacts	Fax:	Email:	Sample SC: <a href="mailto:ABC@investigator.com">ABC@investigator.com</a>
CC:	"CC" Contacts	Fax:	Email:	Sample CRA: <a href="mailto:CRA@xyz.com">CRA@xyz.com</a>
From:	"From" Contacts		Email:	<a href="mailto:236483-imaging@PAREXEL.com">236483-imaging@PAREXEL.com</a>

---

Date: 11-Sep-2017

---

Info	Project: Novartis	Sponsor: Novartis	TIMS: 236483	Protocol: CAIN457K2340
	Investigator	Dr. Investigator		
	Site: XXXX	Site ID: XXXX	Site Name: Investigator Site	DOB:
	Subject: XXXXXXX	Subject ID: XXXXXXX		
	Visit: Screening	Screenin		
		g		

CIL COMMENTS:  
The PAREXEL Core Imaging Laboratory has received acceptable Images and forms of following patient:

Image	Image Modality	Exam Date	Image Series
	X-Ray	02-Sep-2017	SIJ (AP View)

Thank you for submitting the Visit: Screening for Subject: XXXXXXX.  
These images have been accepted. No further action is required. Thank you.

Thank you for your participation!

The information in this communication is intended only for the use of the individual(s) named above. If you are not the intended recipient, or an employee/agent of the recipient who is responsible for delivering this communication, any dissemination, distribution or photocopying or other use of this communication or the information in this information is strictly prohibited. If you received this in error, please call PAREXEL Informatics at 1-878-313-3900, so that we may arrange for the return of the original communication.

Thank you.

---

2 Federal Street, Billerica, MA 01821, USA | [236483-imaging@PAREXEL.com](mailto:236483-imaging@PAREXEL.com)


PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

6.2 Case Query Notification

This form is sent from PAREXEL to the investigator site when unacceptable imaging data is submitted to PAREXEL. The form will describe the issue of concern such as missing data or deviations from the Image Acquisition Guidelines. The form will also indicate the action required.

		2 Federal Street Billerica, MA 01821, USA <a href="mailto:238483-imagino@PAREXEL.com">238483-imagino@PAREXEL.com</a>	
<hr/>			
Query Communication – Novartis CAIN457K2340			
<hr/>			
To:	"To" Contacts	Fax:	Email: <a href="mailto:Sample SC: ABC@investigator.com">Sample SC: ABC@investigator.com</a>
CC:	"CC" Contacts	Fax:	Email: <a href="mailto:Sample CRA: CRA@xyz.com">Sample CRA: CRA@xyz.com</a>
From:	"From" Contacts	Fax:	Email: <a href="mailto:238483-imagino@PAREXEL.com">238483-imagino@PAREXEL.com</a>
<hr/>			
Date:	11-Sep-2017	Query#:	10010
<hr/>			
Info	Project: Investigator Site: Subject: Visit: Query: issue:	Sponsor: Novartis Dr. Investigator Site ID: XXXXX Subject ID: XXXXX Baseline Required Scan Missing Missing Screening	TIMS: 238483 Site Name: Investigator Site DOB:
<hr/>			
CIL COMMENTS: Dear Site / Investigator Please submit the Screening visit image for Subject No. XXXXXXXX. All study related images must be submitted to PAREXEL within 24 hours of acquisitions. Thank You!			
Site COMMENTS:			
<p>The information in this communication is intended only for the use of the individual(s) named above. If you are not the intended recipient, or an employee or agent of the recipient who is responsible for delivering this communication, any dissemination, distribution or photocopying or other use of this communication or the information in this information is strictly prohibited. If you received this in error, please call PAREXEL Informatics at 1-978-313-3900, so that we may arrange for the return of the original communication.</p> <p>Thank you.</p>			
<hr/>			
2 Federal Street, Billerica, MA 01821, USA   <a href="mailto:238483-imagino@PAREXEL.com">238483-imagino@PAREXEL.com</a>			
<hr/>			

PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

6.3 Request Support Form

This form is sent from the investigator site to PAREXEL for the purpose of requesting supplies or for technical or operational support for the imaging portion of the clinical trial.

<b>Request Support Form</b> <b>Novartis CAIN457K2340</b>			
<b>ATTENTION:</b> Project 236483 Team 236483-Imaging@PAREXEL.com PAREXEL Informatics			
<b>REQUESTER:</b> _____			
<b>PI NAME/SITE #:</b> _____			
<b>PHONE #:</b> _____			
<b>DATE:</b> ____/____/____ DD/MM/YYYY			
<b>Nature of Request (Check One):</b> <input type="checkbox"/> Technical <input type="checkbox"/> Operational <input type="checkbox"/> Supplies Needed			
<b>SUPPLIES (Please Indicate Quantity):</b>			
<input type="checkbox"/>	Archive media labels	# _____	(Sheets)
<input type="checkbox"/>	Optical Disks	# _____	
<input type="checkbox"/>	Blank CDs	# _____	
<input type="checkbox"/>	Pre-printed courier airbills	# _____	
<input type="checkbox"/>	Small Padded envelopes for shipping	# _____	
<input type="checkbox"/>	Padded envelopes for X-ray Films	# _____	
<input type="checkbox"/>	Other _____	# _____	
Shipping Address (if different than site address): _____ _____ _____			
<b><u>Operational/Technical Questions:</u></b>   			



PAREXEL International  
Imaging Investigator Site Operations Manual

Novartis / CAIN457K2340 (SURPASS) / Imaging Investigator Site Operations Manual v4.0

---

Signature Approval Page

---

This document has completed a review and is understood and accepted by the following:

---

**Sawata Hiroshi**

---

**Hiroshi Sawata**  
Global Trial Director  
Novartis Pharma AG



Digitally signed by Sawata Hiroshi  
DN: dc=com, dc=novartis, ou=people, ou=GD, serialNumber=606541, cn=Sawata Hiroshi  
Reason: I am approving this document  
Date: 2018.11.26 15:50:44 +01'00'

---

Date

Signatures of the appropriate PAREXEL team members are captured electronically and appended to the last page of this document.

## **PAREXEL International Electronic Signature Page**

This page is the manifestation of the electronic signature(s) used in compliance with PAREXEL International's electronic signature policies and procedures and in compliance with applicable regulations.

UserName: Kayal, Omkar (kayalo)

Title: Project Manager, MEDICAL IMAGING

Date: Tuesday, 27 November 2018, 10:54 AM GMT Standard Time

Meaning: Document contents approved.

=====